BNTX
BioNTech SE
98.60$
-0.5%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +65.2% | -87.3% | -31.4% | +867.2% | -4.4% | -84.6% | +42.7% | +482.4% | -40.8% | -86.6% | -12.0% | – | |
| – | +10.7% | -67.0% | +1.2% | +199.2% | +36.1% | -65.6% | -8.8% | +94.1% | +122.6% | -40.7% | -50.5% | – | |
| – | +77.2% | -90.1% | -46.4% | +1,447.0% | -11.2% | -89.5% | +86.3% | +643.3% | -58.5% | -113.3% | – | – | |
| – | +16.0% | -12.2% | +15.2% | -5.9% | +11.2% | -14.1% | -3.1% | +10.9% | -11.4% | +13.1% | -2.7% | – | |
| – | -5.5% | -11.0% | +46.1% | -22.5% | -16.3% | -3.5% | +10.1% | +3.0% | +100.0% | -49.3% | +28.3% | – | |
| – | +17.2% | -17.8% | +62.8% | +2.0% | -24.4% | -20.7% | +8.3% | +106.8% | -43.6% | -25.4% | +60.5% | – | |
| – | +619.8% | -196.4% | – | – | +1,315.2% | -459.4% | – | – | – | – | – | – | |
| – | +818.8% | -75.0% | +54.3% | -28.8% | +42.0% | -15.9% | -47.1% | -87.9% | +1,513.5% | -36.9% | +94.3% | – | |
| – | +191.6% | -150.0% | – | – | +89.8% | -247.9% | – | – | -1,012.0% | – | – | – | |
| – | +207.3% | -108.1% | – | -2,070.0% | – | -171.0% | – | – | +44.0% | -147.9% | – | – | |
| – | +185.1% | -168.8% | – | – | +31.0% | -260.2% | – | – | – | – | – | – | |
| – | +68.3% | -163.4% | – | – | +120.0% | -179.4% | – | – | -137.2% | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.